Elton John joined Sen. Frist in a opinion urging U.S. officials to move billions in already‑approved AIDS assistance out of Washington and into clinics, saying the moment calls for action not delay.
The two urged immediate delivery of funds Congress provided in the 2025 and 2026 budgets and that the president approved to drive a strategic transition of PEPFAR to country‑led HIV programs. They argued the latest prevention breakthrough — a long‑acting HIV PrEP injection given once every six months — makes it possible to protect millions more people quickly, if the money and doses reach the field.
The case they make rests on blunt numbers: in 2024, 630,000 people died of HIV‑related causes and 1.3 million people acquired HIV. PEPFAR, created in 2003, has been credited with saving more than 26 million lives and preventing roughly 8 million new infections in children while accompanying a fourfold increase in U.S. exports to Africa — but those gains risk stalling if appropriated resources do not leave Washington.
Elton John and Sen. Frist portray the situation as avoidable and urgent. They write that the U.S. government and the Global Fund are already committed to reaching 3 million people over three years with the new prevention drugs, but that demand already outstrips supply and that billions of dollars intended for that work remain parked in Washington rather than being spent where people are dying.
They also press a practical point: community health workers — the frontline staff who would deliver those injections and run accompanying programs — have been terminated in large numbers, widening the gap between policy pledges and real delivery. For the authors, missed rollouts are not abstract bureaucratic failures; they are lives not saved. As they put it, the pause is "not just a tragedy. It's a failure of delivery," and the aim now must be to "get shots in arms."
Context sharpens the authors’ urgency. The piece frames early AIDS responses as improvised — reliant on aspirin, blankets and prayer before modern treatments and prevention existed — and calls PEPFAR one of America’s greatest global achievements. The Global Fund is presented as essential to an orderly handover to country leadership, and the administration’s America First Global Health Strategy is cited as the policy backbone for compacts and innovation funding that should smooth that transition.
The friction is plain: they say "we are closer than ever to ending AIDS," yet the same paragraph lists last year’s 630,000 deaths and 1.3 million new infections, and points to billions of approved dollars that have not reached programs. That contradiction is the story’s pressure point — the technical possibility of ending AIDS, made real by new tools, versus the political and logistical reality that funding and personnel are not yet where they must be.
The authors offer a concrete next move. They urge the State Department and the Global Fund to consider doubling their rollout plan for the new prevention drugs so that the pledged resources match the scale of demand and the potential of the six‑monthly PrEP injections. The decision to accelerate distribution — and to push appropriated funds out of Washington into country programs and rehired community health workers — is the immediate test of whether the world’s stated progress will convert into fewer deaths and infections.
If U.S. and Global Fund leaders agree to speed the rollout, millions could be reached sooner; if they do not, the paper commitments approved in 2025 and 2026 will remain precisely that — commitments on paper while 630,000 people continue to die each year. The real question now is not whether the tools exist, but whether Washington will let them leave town.
